PolyPid Announces Recruitment of First Patient In Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ For Prevention Of Abdominal Colorectal Surgical Site Infections
Portfolio Pulse from Bill Haddad
PolyPid has announced the recruitment of the first patient in its revised SHIELD II Phase 3 trial, which evaluates D-PLEX₁₀₀ for the prevention of abdominal colorectal surgical site infections.
June 22, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid has started recruiting patients for its revised SHIELD II Phase 3 trial, evaluating D-PLEX₁₀₀ for preventing abdominal colorectal surgical site infections.
The recruitment of the first patient in the revised SHIELD II Phase 3 trial is a positive development for PolyPid, as it indicates progress in the evaluation of D-PLEX₁₀₀. If the trial results are positive, it could lead to increased demand for the product and potential revenue growth for the company.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100